{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T21:42:40Z","timestamp":1778276560072,"version":"3.51.4"},"reference-count":31,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"KL2 RR024983"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpurol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Urology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.jpurol.2012.12.005","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T22:22:06Z","timestamp":1359670926000},"page":"884-889","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"PA","title":["Prevalence and spot urine risk factors for renal stones in children taking topiramate"],"prefix":"10.1016","volume":"9","author":[{"given":"Nicol","family":"Corbin Bush","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Twombley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naim M.","family":"Maalouf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khashayar","family":"Sakhaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpurol.2012.12.005_bib1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2008-0642","article-title":"Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of topiramate for migraine prevention in pediatric subjects 12 to 17 years of age","volume":"123","author":"Lewis","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpurol.2012.12.005_bib2","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1528-1167.2010.02598.x","article-title":"Pharmacokinetic-pharmacodynamic assessment of topiramate dosing regimens for children with epilepsy 2 to <10 years of age","volume":"51","author":"Girgis","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpurol.2012.12.005_bib3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-1211(02)00103-1","article-title":"Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study","volume":"51","author":"Coppola","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jpurol.2012.12.005_bib4","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0920-1211(02)00010-4","article-title":"Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial","volume":"49","author":"Coppola","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jpurol.2012.12.005_bib5","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/WNF.0b013e3181c295c1","article-title":"Topiramate in treatment of tourette syndrome","volume":"33","author":"Kuo","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib6","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1089\/cap.2009.0042","article-title":"Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder","volume":"19","author":"Wozniak","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib7","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.pnpbp.2010.07.005","article-title":"Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder","volume":"34","author":"Rezaei","year":"2010","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpurol.2012.12.005_bib8","first-page":"701","article-title":"Topiramate-induced metabolic acidosis: report of two cases","volume":"43","author":"Ko","year":"2001","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1046\/j.1528-1157.2001.04500.x","article-title":"Topiramate and metabolic acidosis in pediatric epilepsy","volume":"42","author":"Takeoka","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpurol.2012.12.005_bib10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1046\/j.1528-1157.2002.37201.x","article-title":"Topiramate and metabolic acidosis in infants and toddlers","volume":"43","author":"Philippi","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpurol.2012.12.005_bib11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejpn.2009.11.004","article-title":"Chronic impact of topiramate on acid-base balance and potassium in childhood","volume":"14","author":"Belotti","year":"2010","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib12","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1460-9592.2005.01415.x","article-title":"Topiramate and metabolic acidosis: a case series and review of the literature","volume":"15","author":"Groeper","year":"2005","journal-title":"Paediatr Anaesth"},{"issue":"Suppl. 1","key":"10.1016\/j.jpurol.2012.12.005_bib13","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1111\/j.1528-1157.2000.tb06047.x","article-title":"Topiramate as an inhibitor of carbonic anhydrase isoenzymes","volume":"41","author":"Dodgson","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpurol.2012.12.005_bib14","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.6.5.547","article-title":"Increased propensity for calcium phosphate kidney stones with topiramate use","volume":"6","author":"Vega","year":"2007","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jpurol.2012.12.005_bib15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1053\/j.ajkd.2006.07.003","article-title":"Biochemical and stone-risk profiles with topiramate treatment","volume":"48","author":"Welch","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jpurol.2012.12.005_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.urology.2008.01.042","article-title":"Induction of progressive profound hypocitraturia with increasing doses of topiramate","volume":"72","author":"Warner","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2012.12.005_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1258\/000456304322880104","article-title":"Topiramate increases biochemical risk of nephrolithiasis","volume":"41","author":"Lamb","year":"2004","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.jpurol.2012.12.005_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.urology.2010.06.048","article-title":"Patients with and without prior urolithiasis have hypocitraturia and incident kidney stones while on topiramate","volume":"77","author":"Kaplon","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.jpurol.2012.12.005_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00240-010-0347-5","article-title":"Nephrolithiasis in topiramate users","volume":"39","author":"Maalouf","year":"2011","journal-title":"Urol Res"},{"key":"10.1016\/j.jpurol.2012.12.005_bib20","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1046\/j.1523-1755.2003.00917.x","article-title":"Time trends in reported prevalence of kidney stones in the United States: 1976-1994","volume":"63","author":"Stamatelou","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.jpurol.2012.12.005_bib21","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/j.1528-1167.2011.03245.x","article-title":"Incidence of kidney stones with topiramate treatment in pediatric patients","volume":"52","author":"Mahmoud","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpurol.2012.12.005_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.pediatrneurol.2008.11.004","article-title":"Urolithiasis with topiramate in nonambulatory children and young adults","volume":"40","author":"Goyal","year":"2009","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1542\/pir.25-4-131","article-title":"Nephrolithiasis in children","volume":"25","author":"Gillespie","year":"2004","journal-title":"Pediatr Rev"},{"key":"10.1016\/j.jpurol.2012.12.005_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00240-010-0306-1","article-title":"Metabolic and demographic characteristics of children with urolithiasis in Western Turkey","volume":"39","author":"Ertan","year":"2011","journal-title":"Urol Res"},{"key":"10.1016\/j.jpurol.2012.12.005_bib25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/adc.74.4.350","article-title":"Hypocitraturia in patients with urolithiasis","volume":"74","author":"Akcay","year":"1996","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jpurol.2012.12.005_bib26","series-title":"Clinical pediatric urology","first-page":"1223","article-title":"Pediatric urolithiasis","author":"Belman","year":"2002"},{"key":"10.1016\/j.jpurol.2012.12.005_bib27","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1007\/s00467-009-1231-9","article-title":"Clinical and metabolic features of urolithiasis and microlithiasis in children","volume":"24","author":"Alpay","year":"2009","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1007\/s00467-008-0769-2","article-title":"Metabolic risk factors in children with kidney stone disease","volume":"23","author":"Spivacow","year":"2008","journal-title":"Pediatr Nephrol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib29","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/S0022-5347(05)64217-6","article-title":"Metabolic evaluation of children with urolithiasis: are adult references for supersaturation appropriate?","volume":"168","author":"Battino","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib30","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0022-5347(05)67238-2","article-title":"The role of hypercalciuria in a subgroup of dysfunctional voiding syndromes of childhood","volume":"164","author":"Parekh","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.jpurol.2012.12.005_bib31","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1097\/01.ju.0000140959.32579.44","article-title":"Elucidation of factors determining formation of calcium phosphate stones","volume":"172","author":"Pak","year":"2004","journal-title":"J Urol"}],"container-title":["Journal of Pediatric Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513112002975?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477513112002975?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:38:27Z","timestamp":1761485907000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477513112002975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S1477513112002975"],"URL":"https:\/\/doi.org\/10.1016\/j.jpurol.2012.12.005","relation":{},"ISSN":["1477-5131"],"issn-type":[{"value":"1477-5131","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence and spot urine risk factors for renal stones in children taking topiramate","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpurol.2012.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}